Expression of Her-2eu in endometrial carcinoma and its relation with clinicopathological variables

摘要

Objective and background : Her-2eu tyrosine kinase has been implicated in the development and progression of several human cancers and is target for therapeutic intervention. Smaller studies suggest that Her-2eu may be involved in the tumerogenesis of endometrial adenocarcinoma. The aim of this study was to evaluate Her-2eu expression in endometrial carcinoma (EC) and its correlation with clinicopathological features in order to define the potential prognostic value of Her-2eu overexpression in EC . Patients and methods: Nineteen patients with stage I-IV EC were included in this study. Demographic, clinical and pathologic information was obtained and recorded. Her-2eu expression was evaluated by immunohistochemistry (IHC) on paraffin embedded tissue sections with Her-2eu antibody. Overexpression was defined as complete membrane staining in greater than 10% of cells. Results : The positive rate of Her-2eu in EC was 42.1%. Her-2eu was associated with surgical stage (p0.05). Conclusion: Our study provides evidence of Her-2eu overexpression in a considerable proportion of the patients with uterine adenocarcinoma, thus suggesting the opportunity for the possible use of anti-Her-2eu therapy in this malignancy by selective inhibition of Her-2eu. The use of Herceptin, a monoclonal antibody directed against Her-2eu, for therapy of patients harboring Her-2eu positive EC may be beneficial. Her-2eu overexpression is related to most of the prognostic variables of EC and may be incorporated into the criteria for determination of tumor aggressiveness as a prognostic marker